
    
      Purpose: This study will be a single arm, prospective cohort study to examine the safety,
      efficacy, and pharmacokinetic and metabolic characteristics of Raltegravir in
      African-American men and women.

      Participants: 40 HIV positive, ARV treatment-naive, African-American women and men (estimated
      to be 70% men, 30% women)

      Procedures (methods): Subjects will receive Raltegravir 400 mg BID along with Truvada for 104
      weeks.
    
  